source
- FDA approves Regeneron’s garetosmab for ultra-rare bone-forming diseaseThe FDA has granted approval to Regeneron's antibody garetosmab, which targets activin A, for the treatment of fibrodysplasia ossificans progressiva (FOP). FOP is an ultra‑rare disorder that causes…
- Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategyTScan has told Fierce that its pipeline strategy remains unchanged despite Amgen walking away from a Crohn’s disease collaboration that had the potential for a windfall of half a billion dollars.Fierce Biotech · 17h ago↗ source